Small molecule · developed by Jazz Pharmaceuticals
Cannabidivarin (CBDV) is a cannabinoid studied at a dose of 10 mg/kg/day in autism spectrum disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03202303 | Phase 2 | Autism Spectrum Disorder | Completed | JAZZ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autism Spectrum Disorder
Updated Nov 8, 2026. Something wrong or missing? Report it on the JAZZ page.
See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JAZZ catalysts and pipeline →